The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Open accessAbstract
Preclinical studies suggest that treatment with neoadjuvant immune checkpoint blockade is associated with enhanced survival and antigen-specific T cell responses compared with adjuvant treatment1; however, optimal regimens have not been defined. Here we report results from a randomized phase 2 study of neoadjuvant nivolumab versus combined ipilimumab with nivolumab in 23 patients with high-risk resectable melanoma (NCT02519322). RECIST overall response rates (ORR), pathologic complete response rates (pCR), treatment-related adverse events (trAEs) and immune correlates of response were assessed. Treatment with combined ipilimumab and nivolumab yielded high response rates (RECIST ORR 73%, pCR 45%) but substantial toxicity (73% grade 3 trAEs), whereas treatment with nivolumab monotherapy yielded modest responses (ORR 25%, pCR 25%) and low toxicity (8% grade 3 trAEs). Immune correlates of response were identified, demonstrating higher lymphoid infiltrates in responders to both therapies and a more clonal and diverse T cell infiltrate in responders to nivolumab monotherapy. These results describe the feasibility of neoadjuvant immune checkpoint blockade in melanoma and emphasize the need for additional studies to optimize treatment regimens and to validate putative biomarkers. Neoadjuvant combination treatment with nivolumab and ipilimumab in patients with high-risk melanoma results in higher response rates than nivolumab monotherapy and warrants future optimization of dosing regimens to preserve efficacy while limiting toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“analyses of samples derived from patients with melanoma who received neoadjuvant ICIs112,113 have revealed the presence of the three primary patterns of T cell infiltration identified in solid tumours.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [113]
Experimental — accuracy not yet measuredIn the citing paper
“Studies in melanoma using higher dosages of ipilimumab reported enhanced immune infiltration in responding tumors17.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [17]
In the citing paper
“Amaria and colleagues17 demonstrated that a more clonal T-cell repertoire at baseline correlated with response to neoadjuvant ICI therapy in patients with melanoma, with further expansion of the pre-existing high-frequency clones with treatment.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [17]
In the citing paper
“Key roles of TGF-β1 in suppressing the adaptive immune system are apparent from the lymphoproliferative autoimmune phenotype of Tgfb1−/− mice197–199, and similar phenotypes following selective ablation of TGF-β signaling components within CD4+ and CD8+ T cells200.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [198]
In the citing paper
“Clinical trials with ICT in the neoadjuvant setting have now demonstrated clinical benefit in multiple tumor types, including melanoma (173, 174), Merkel cell carcinoma (175), NSCLC (176), MMRdeficient colorectal cancer (177), urothelial carcinoma (21, 178), and breast cancer (179-181).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [173]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R. E., Garimella, K. V., Maguire, J., Hartl, C., Philippakis, A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,508
Edge, S. B., & Compton, C. C. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0985-4 · Cited by 9,055
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Acute Abdomen: A Rare Case of Ruptured Hepatocellular Carcinoma
Gloor, S., Jensen, K. O., Breitenstein, S., Binkert, C. A., Angst, E., & Hetzer, F. H. (2017) · Case Reports in Gastroenterology · doi:10.1159/000463378 · Cited by 5,370
Research works printed but not linked: 1
- Edge, S. B. AJCC Cancer Staging Manual 7th edn (Springer, New York, 2010).
Cited by
Sorted by citations
Items 301–400 of 838
Iivanainen, S., & Koivunen, J. P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020556 · Cited by 30
Cai, Y., Wang, X., Wang, N., Wu, J., Ma, L., Xie, X., Zhang, H., Dang, C., Kang, H., Zhang, S., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119505 · Cited by 30
Self-citationBarth, D. A., Stanzer, S., Terzic, J. A., Bauernhofer, T., Absenger, G., Szkandera, J., Gerger, A., Smolle, M. A., Hutterer, G. C., Ahyai, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.840207 · Cited by 30
Hieken, T. J., Nelson, G. D., Flotte, T. J., Grewal, E. P., Chen, J., McWilliams, R. R., Kottschade, L. A., Yang, L., Domingo‐Musibay, E., Dronca, R. S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45798-8 · Cited by 32
Neoadjuvant systemic therapy for hepatocellular carcinoma
Chick, R. C., Ruff, S. M., & Pawlik, T. M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1355812 · Cited by 28
Jackett, L. A., & Scolyer, R. A. (2019) · Cancers · doi:10.3390/cancers11122041 · Cited by 30
Keung, E. Z.-Y., & Gershenwald, J. E. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa012 · Cited by 29
Self-citationTobias, J., Battin, C., Linhares, A. D. S., Lebens, M., Baier, K., Ambroz, K., Drinić, M., Högler, S., Inić‐Kanada, A., Garner‐Spitzer, E., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00895 · Cited by 28
Lü, Y., Ng, A. H. C., Chow, F. E., Everson, R. G., Helmink, B. A., Tetzlaff, M. T., Thakur, R., Wargo, J. A., Cloughesy, T. F., Prins, R. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24293-4 · Cited by 30
Self-citationChen, J. A., Ma, W., Yuan, J. D., & Li, T. (2020) · Cancer treatment and research · doi:10.1007/978-3-030-38862-1_9 · Cited by 29
Maio, M., Blank, C. U., Necchi, A., Giacomo, A. M. D., Ibrahim, R. A., Lahn, M., Fox, B. A., Bell, R. B., Tortora, G., & Eggermont, A. M. M. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.04.035 · Cited by 28
Rossi, N., Lee, K. A., Bermudez, M. V., Visconti, A., Thomas, A. M., Bolte, L. A., Björk, J. R., de Ruijter, L. K., Newton‐Bishop, J., Harland, M., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104235 · Cited by 29
Neoadjuvant treatment for stage III and IV cutaneous melanoma
Gorry, C., McCullagh, L., O’Donnell, H., Barrett, S., Schmitz, S., Barry, M. G., Curtin, K., Beausang, E. S., Barry, R., & Coyne, I. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012974.pub2 · Cited by 28
Neoadjuvant Immunotherapy: A Promising New Standard of Care
Boydell, E., Sandoval, J. L., Michielin, O. A., Obéid, M., Addeo, A., & Friedlaender, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411849 · Cited by 30
Adegoke, N. A., Gide, T. N., Mao, Y., Quek, C. Y. J., Patrick, E., Carlino, M. S., Lo, S., Menzies, A. M., da Silva, I. P., Vergara, I. A., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007144 · Cited by 30
Lian, W., Jiang, D., Lin, W., Jiang, M., Zhang, Y., Wang, H. Z., & Zhao, L. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.87440 · Cited by 27
Cheng, J., Guo, M., Yang, Y., Liu, Y., Hu, W., Shang, Q., Li, C., Xia, L., Wang, Y., Wang, W., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.848881 · Cited by 27
The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy
Lee, J. Y., Kannan, B., Lim, B. Y., Li, Z., Lim, A. H., Loh, J. W., Ko, T. K., Ng, C. C. Y., & Chan, J. Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147839 · Cited by 29
Self-citationHe, T., Hu, M., Zhu, S., Shen, M., Kou, X., Liang, X., Li, L., Li, X., Zhang, M., Wu, Q., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.09.017 · Cited by 27
Gross, E. E., Li, M., Yin, M., Orcutt, D. J., Hussey, D., Trott, E., Holt, S. K., Dwyer, E. R., Kramer, J. H., Oliva, K., et al. (2022) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2022.08.013 · Cited by 30
Badani, A., Ozair, A., Khasraw, M., Woodworth, G. F., Tiwari, P., Ahluwalia, M. S., & Mansouri, A. (2024) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04881-2 · Cited by 26
Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma
Najjar, Y. G., McCurry, D., Huang, L., Lin, Y., Zang, Y., Davar, D., Karunamurthy, A. D., Drabick, J. J., Neves, R. I., Butterfield, L. H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4301 · Cited by 28
Immunotherapy for Triple-Negative Breast Cancer
Cao, Y., Chen, C., Tao, Y., Lin, W., & Wang, P. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122003 · Cited by 28
The promise and challenge of spatial omics in dissecting tumour microenvironment and the role of AI
Lee, R. Y., Ng, C. W., Rajapakse, M. P., Ang, N., Yeong, J. P.-S., & Lau, M. C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1172314 · Cited by 28
Risk-based stratification in head and neck mucosal melanoma
Moya‐Plana, A., Mangin, D., Dercle, L., Taouachi, R., Casiraghi, O., Ammari, S., Nguyen, F., Temam, S., Robert, C., & Gorphe, P. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.07.026 · Cited by 26
Wispelaere, W. D., Annibali, D., Tuyaerts, S., Messiaen, J., Antoranz, A., Shankar, G., Dubroja, N., Herreros‐Pomares, A., Baiden-Amissah, R. E. M., Orban, M., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1655 · Cited by 25
PLAN B for immunotherapy: Promoting and leveraging anti-tumor B cell immunity
Shi, Y. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.09.028 · Cited by 25
Systemic adjuvant therapy for high-risk cutaneous melanoma
Kobeissi, I., & Tarhini, A. A. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221134087 · Cited by 25
Lai-Kwon, J. E., Inderjeeth, A., Lisy, K., Sandhu, S. K., Rutherford, C., & Jefford, M. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.02.005 · Cited by 24
Nie, R., Chen, F., Provencio, M., Wang, Y., van den Ende, T., van Laarhoven, H. W. M., Yuan, S., Pless, M., Hayoz, S., Zhou, Z., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.03.010 · Cited by 25
Park, J., Lee, J. B., Lim, M. C., Lim, M. C., Kim, B., Kim, J., Choi, C. H., Kim, H. S., Park, S. Y., & Lee, J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007444 · Cited by 25
Self-citationNeoadjuvant Immunotherapy for Locally Advanced Melanoma
Pelster, M. S., & Amaria, R. N. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-0700-z · Cited by 26
Self-citationHow to Make Immunotherapy an Effective Therapeutic Choice for Uveal Melanoma
Marseglia, M., Amaro, A. A., Solari, N., Gangemi, R. M. R., Croce, E., Tanda, E. T., Spagnolo, F., Filaci, G., Pfeffer, U., & Croce, M. (2021) · Cancers · doi:10.3390/cancers13092043 · Cited by 24
Adjuvant Therapy and Prognosticators of Survival in Head and Neck Mucosal Melanoma
Abiri, A., Yasaka, T. M., Lehrich, B. M., Goshtasbi, K., Papagiannopoulos, P., Tajudeen, B. A., John, M. A. S., Harris, J. P., & Kuan, E. C. (2021) · The Laryngoscope · doi:10.1002/lary.29807 · Cited by 24
Xiang, Z., Li, J., Zhang, Z., Cen, C., Chen, W., Jiang, B., Meng, Y., Wang, Y., Berglund, B., Zhai, G., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.883655 · Cited by 23
Fujimura, T., Muto, Y., & Asano, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415720 · Cited by 26
Current Strategy to Treat Immunogenic Gastrointestinal Cancers: Perspectives for a New Era
Shimozaki, K., Nakayama, I., Hirota, T., & Yamaguchi, K. (2023) · Cells · doi:10.3390/cells12071049 · Cited by 25
How Can the Microbiome Induce Carcinogenesis and Modulate Drug Resistance in Cancer Therapy?
Mendes, I., & Vale, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411855 · Cited by 24
Savas, P. S., Virassamy, B., Ye, C., Salim, A., Mintoff, C., Caramia, F., Salgado, R., Byrne, D. J., Teo, Z. L., Dushyanthen, S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0176-6 · Cited by 24
Clinical benefit of neoadjuvant anti‐PD‐1/PD‐L1 utilization among different tumors
Li, Z., Wu, X., Zhao, Y., Xiao, Y., Zhao, Y., Zhang, T., Li, H., Sha, F., Wang, Y., Deng, L., et al. (2021) · MedComm · doi:10.1002/mco2.61 · Cited by 23
Zhao, Y., Li, D., Zhuang, J., Li, Z., Xia, Q., Li, Z., Yu, J., Wang, J., Zhang, Y., Li, K., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1674 · Cited by 23
Clinical Evidence for Microbiome-Based Strategies in Cancer Immunotherapy: A State-of-the-Art Review
Petrelli, F., Ghidini, A., Dottorini, L., Ghidini, M., Zaniboni, A., & Tomasello, G. (2025) · Medicina · doi:10.3390/medicina61091595 · Cited by 30
Dahl, O., & Brydøy, M. (2019) · Acta Oncologica · doi:10.1080/0284186x.2018.1555375 · Cited by 24
PD‑1/PD‑L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review)
Tang, Q., Zhao, S., Zhou, N., He, J., Zu, L., Liu, T., Song, Z., Chen, J., Peng, L., & Xu, S. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5497 · Cited by 25
Gögenur, M., Balsevicius, L., Bulut, M., Colak, N. Ö., Justesen, T. F., Fiehn, A. K., Jensen, M. B., Høst-Rasmussen, K., Cappelen, B., Gaggar, S., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006774 · Cited by 23
Biomarker-Driven Personalization of Neoadjuvant Immunotherapy in Melanoma
Hoeijmakers, L. L., Reijers, I. L. M., & Blank, C. U. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0352 · Cited by 24
Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma
Mangla, A., Lee, C., Mirsky, M. M., Wang, M., Rothermel, L. D., Hoehn, R. S., Bordeaux, J. S., Carroll, B. T., Theuner, J., Li, S., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2023.7333 · Cited by 25
Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer
Huynh, C., Walsh, L. A., & Spicer, J. D. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-509 · Cited by 23
Robust immunoscore model to predict the response to anti-PD1 therapy in melanoma
Nie, R., Yuan, S., Wang, Y., Chen, Y.-B., Cai, Y.-Y., Chen, S., Li, S.-M., Zhou, J., Chen, G., Luo, T., et al. (2019) · Aging · doi:10.18632/aging.102556 · Cited by 23
Adjuvant systemic therapy in high-risk melanoma
Blankenstein, S. A., & van Akkooi, A. C. J. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000604 · Cited by 23
Newcomer, K., Robbins, K. J., Perone, J., Hinojosa, F. L., Chen, D., Jones, S. A., Kaufman, C. K., Weiser, R., Fields, R. C., & Tyler, D. S. (2021) · Current Problems in Surgery · doi:10.1016/j.cpsurg.2021.101030 · Cited by 22
Penile cancer: Updates in systemic therapy
Joshi, V. B., Chadha, J. S., & Chahoud, J. (2022) · Asian journal of urology · doi:10.1016/j.ajur.2022.03.006 · Cited by 23
Zhao, M., Chen, S., Li, C., Du, Y., & Li, P. (2023) · Cancers · doi:10.3390/cancers15030600 · Cited by 23
Yu, J., Zhikun, G., & Wang, L. (2023) · Life · doi:10.3390/life13051189 · Cited by 22
Self-citationSpatial omics techniques and data analysis for cancer immunotherapy applications
Zhang, Y., Lee, R. Y., Tan, C. W., Guo, X., Yim, W. W., Lim, J., Wee, F. Y. T., Wu, Y., Kharbanda, M., Lee, J.-Y. J., et al. (2024) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2024.103111 · Cited by 23
Self-citationGutiérrez, V., González, A. C., Gálvez, L., Lizarralde, Y. A., & Rueda‐Domínguez, A. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920984061 · Cited by 21
Next Steps for Immunotherapy in Glioblastoma
Cao, T., Wainwright, D. A., Lee-Chang, C., Miska, J. M., Sonabend, A. M., Heimberger, A. B., & Lukas, R. V. (2022) · Cancers · doi:10.3390/cancers14164023 · Cited by 21
Wollina, U. (2022) · Dermatologic Therapy · doi:10.1111/dth.15966 · Cited by 23
Relatlimab and nivolumab in the treatment of melanoma
Au, L., Larkin, J., & Turajlic, S. (2022) · Cell · doi:10.1016/j.cell.2022.12.003 · Cited by 21
Wang, Y., Yang, S., Wan, L., Ling, W., Chen, H. H., & Wang, J. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5534 · Cited by 22
McSorley, S. T., Lau, H. Y. N., McIntosh, D., Forshaw, M. J., McMillan, D. C., & Crumley, A. B. C. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09074-5 · Cited by 21
Surgery for Metastatic Melanoma: an Evolving Concept
Testori, A., Blankenstein, S. A., & van Akkooi, A. C. J. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0847-6 · Cited by 21
Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma
Akula, V., Chen, L., Açıkgöz, Y., Klein, K., Yavuz, B. G., Cevik, L., Demir, T., Manne, A., Şahin, İ., Kaseb, A. O., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00846-4 · Cited by 24
Vion, R., Dugage, M. R., Flippot, R., Ouali, K., Rouanne, M., Clatot, F., Sellars, M., Champiat, S., Chaput, N., Massard, C., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115572 · Cited by 21
Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancer
Gust, K. M., Rebhan, K., Resch, I., Shariat, S. F., & Necchi, A. (2020) · Current Opinion in Urology · doi:10.1097/mou.0000000000000783 · Cited by 20
Isolated limb perfusion for locally advanced melanoma in the immunotherapy era
Davies, E. J., Reijers, S. J. M., van Akkooi, A. C. J., van Houdt, W. J., & Hayes, A. J. (2022) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2022.01.027 · Cited by 20
Chen, J., Chen, J., & Wang, L. (2022) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200174 · Cited by 21
Self-citationLiu, M., Wang, X., Du, X., Wu, W., Zhang, Y., Zhang, P., Ai, C., Devenport, M., Su, J., Muthana, M. M., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abm5663 · Cited by 20
Panian, J. A., Saidian, A., Hakimi, K. N., Ajmera, A., Anderson, W. J., Barata, P. C., Berg, S. A., Signoretti, S., Chang, S. L., D’Andrea, V. D., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad166 · Cited by 22
Self-citationFactors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma
Loo, K. L., Smithy, J. W., Postow, M. A., & Warner, A. B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.810388 · Cited by 23
Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphomaPreprint
Phillips, D. J., Matusiak, M., Rivero‐Gutiérrez, B., Bhate, S. S., Barlow, G. L., Jiang, S., Demeter, J., Smythe, K. S., Pierce, R. H., Fling, S. P., et al. (2020) · medRxiv · doi:10.1101/2020.12.06.20244913 · Cited by 20
Gorbokon, N., Wößner, N., Ahlburg, V., Plage, H., Hofbauer, S. L., Furlano, K., Weinberger, S., Bruch, P. G., Schallenberg, S., Roßner, F., et al. (2024) · The Journal of Pathology Clinical Research · doi:10.1002/2056-4538.70012 · Cited by 19
Shang, Q., Jiang, C., Guo, M., Tang, M., Yang, J., Xie, J., An, X., Zhang, Q., & Wang, F. (2026) · Science Advances · doi:10.1126/sciadv.adx9671 · Cited by 19
A B‐cell or a key player? The different roles of B‐cells and antibodies in melanoma
Rodgers, C. B., Mustard, C. J., McLean, R. T., Hutchison, S., & Pritchard, A. L. (2022) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13031 · Cited by 18
A View on Drug Development for Cancer Prevention
Reynolds, A. R., Moschetta, M., Yohannes, A. R., Walcott, F. L., Ashford, M. B., Szűcs, Z., Sarbajna, T., Hadfield, J., Harrison, E., Challis, B., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0776 · Cited by 21
Hassel, J. C., Zimmer, L., Sickmann, T., Eigentler, T., Meier, F. E., Mohr, P., Pukrop, T., Roesch, A., Vordermark, D., Wendl, C. M., et al. (2023) · Cancers · doi:10.3390/cancers15133448 · Cited by 21
Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response
Navani, V., Graves, M. C., Bowden, N. A., & van der Westhuizen, A. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14352 · Cited by 20
Rationalizing the pathway to personalized neoadjuvant immunotherapy: the Lombard Street Approach
Versluis, J. M., Thommen, D. S., & Blank, C. U. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001352 · Cited by 20
Davies, M. A. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00136 · Cited by 18
Self-citationFallarino, F., & Blank, C. U. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01222-w · Cited by 23
Prognostic value and therapeutic implications of nodal involvement in head and neck mucosal melanoma
Moya‐Plana, A., Mangin, D., Blanchard, P., Obongo, R., Casiraghi, O., Bidault, F., Temam, S., Robert, C., & Gorphe, P. (2021) · Head & Neck · doi:10.1002/hed.26694 · Cited by 18
Neoantigen-Reactive T Cells: The Driving Force behind Successful Melanoma Immunotherapy
Davis, L., Tarduno, A., & Lu, Y. (2021) · Cancers · doi:10.3390/cancers13236061 · Cited by 18
RNA m6A modification in prostate cancer: A new weapon for its diagnosis and therapy
Han, Z., Yi, X., Li, J., Zhang, T., Liao, D., You, J. E., & Ai, J. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188961 · Cited by 18
Xu, F., Zhu, H., Xiong, D., Wang, K., Dong, Y., Li, L., & Yuan, S. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15175 · Cited by 18
Neoadjuvant Immunotherapy: An Evolving Paradigm Shift?
Bilušić, M., & Gulley, J. L. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa217 · Cited by 19
Next Generation Imaging Techniques to Define Immune Topographies in Solid Tumors
Pietrobon, V., Cesano, A., Marincola, F. M., & Kather, J. N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.604967 · Cited by 18
Spatial profiling technologies and applications for brain cancers
Croft, P. K., Sadeghirad, H., Gasper, H. M., O'Byrne, K. J., Lakhani, S. R., & Kulasinghe, A. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1900735 · Cited by 18
Yin, G.-Q., Li, Z.-L., & Li, D. (2022) · Cancer Management and Research · doi:10.2147/cmar.s358620 · Cited by 17
Current surgical management for melanoma
Koizumi, S., Inozume, T., & Nakamura, Y. (2023) · The Journal of Dermatology · doi:10.1111/1346-8138.17086 · Cited by 19
Myers, S. P., Sevilimedu, V., Jones, V. M., Abuhadra, N. K., Montagna, G., Plitas, G., Morrow, M., & Downs‐Canner, S. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-15359-w · Cited by 19
Monette, A., Warren, S., Barrett, J. C., Garnett‐Benson, C., Schalper, K. A., Taube, J. M., Topp, B. G., & Snyder, A. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009427 · Cited by 17
The Role and Necessity of Sentinel Lymph Node Biopsy for Invasive Melanoma
Nakamura, Y. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00231 · Cited by 17
Cutaneous Melanoma – A Review of Systemic Therapies
Lee, K., & Nathan, P. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3496 · Cited by 21
Protein-based immune profiles of basal-like vs. luminal breast cancers
Walens, A., Olsson, L. T., Gao, X., Hamilton, A. M., Kirk, E. L., Cohen, S. M., Midkiff, B. R., Xia, Y., Sherman, M. E., Nikolaishvili‐Feinberg, N., et al. (2021) · Laboratory Investigation · doi:10.1038/s41374-020-00506-0 · Cited by 17
Breukers, S. E., Traets, J. J. H., van Dijk, S. W., Ostos, M. M., Fraterman, I., Crommelin, R. D., van der Hulst, H. J., Qiao, X., Boere, T., van de Poll-Franse, L. V., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03943-w · Cited by 20
Surgical Considerations and Systemic Therapy of Melanoma
Gamboa, A. C., Lowe, M., Yushak, M. L., & Delman, K. A. (2019) · Surgical Clinics of North America · doi:10.1016/j.suc.2019.09.012 · Cited by 16
Pradeep, J., Win, T. T., Aye, S. N., & Sreeramareddy, C. T. (2022) · Journal of Cancer · doi:10.7150/jca.72210 · Cited by 17
Zhou, J., Liang, R., Wang, H.-T., Jin, S., Hu, W., Frey, B., Fietkau, R., Hecht, M., Ma, H., & Gaipl, U. S. (2023) · Neoplasia · doi:10.1016/j.neo.2023.100877 · Cited by 18
Neoadjuvant Immune Checkpoint Inhibition in Metastatic Conjunctival Melanoma
Fan, K., Waninger, J. J., Yentz, S. E., McLean, S. A., & Demirci, H. (2023) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000002407 · Cited by 16
Epidemiology, staging and management of mucosal melanoma of the head and neck: a narrative review
Jeong, Y. J., Thompson, J. F., & Ch’ng, S. (2023) · Chinese Clinical Oncology · doi:10.21037/cco-23-16 · Cited by 16
Metadata
- Authors
- Amaria, R. N., Reddy, S. M., Tawbi, H. A., Davies, M. A., Ross, M. I., Glitza, I. C., Cormier, J. N., Lewis, C., Hwu, W.-J., Hanna, E., Diab, A., Wong, M. K., Royal, R., Gross, N., Weber, R., Lai, S. Y., Ehlers, R., Blando, J., Milton, D. R., Woodman, S., Kageyama, R., Wells, D. K., Hwu, P., Patel, S. P., Lucci, A., Hessel, A., Lee, J. E., Gershenwald, J., Simpson, L., Burton, E. M., Posada, L., Haydu, L., Wang, L., Zhang, S., Lazar, A. J., Hudgens, C. W., Gopalakrishnan, V., Reuben, A., Andrews, M. C., Spencer, C. N., Prieto, V., Sharma, P., Allison, J., Tetzlaff, M. T., & Wargo, J. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Parker Institute for Cancer Immunotherapy (US)
- Corresponding author
- Wargo, Jennifer A.
- ORCID
- Amaria, Rodabe N.
- Reddy, Sangeetha M.
- Tawbi, Hussein A.
- Davies, Michael A.
- Ross, Merrick I.
- Cormier, Janice N.
- Lewis, Carol
- Hwu, Wen-Jen
- Hanna, Ehab
- Diab, Adi
- Wong, Michael K.
- Gross, Neil
- Weber, Randal
- Lai, Stephen Y.
- Blando, Jorge
- Woodman, Scott
- Kageyama, Robin
- Wells, Daniel K.
- Hwu, Patrick
- Patel, Sapna P.
- Lucci, Anthony
- Lee, Jeffrey E.
- Gershenwald, Jeffrey
- Burton, Elizabeth M.
- Haydu, Lauren
- Wang, Linghua
- Zhang, Shaojun
- Lazar, Alexander J.
- Hudgens, Courtney W.
- Gopalakrishnan, Vancheswaran
- Reuben, Alexandre
- Andrews, Miles C.
- Spencer, Christine N.
- Prieto, Victor
- Sharma, Padmanee
- Allison, James
- Tetzlaff, Michael T.
- Wargo, Jennifer A.
- Venue
- Nature Medicine
- Published
- 2018-10-08
- Volume
- 24
- Issue
- 11
- Pages
- 1649-1654
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC6481682
- OpenAlex
- W2894584497
- Semantic Scholar
- 251ac2984307dc31d5a4596caa7a07c90195b1e8
- Cited by
- 835
- References
- 31
- Citations by year
- 2026: 49 · 2025: 80 · 2024: 102 · 2023: 116 · 2022: 119 · 2021: 130 · 2020: 142 · 2019: 79 · 2018: 12
- FWCI
- 34.49
- Type
- journal article
- Language
- en
- Update notices
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Defense
- Bristol-Myers Squibb
- Nature
- National Institutes of Health (UL1TR000371)
- University of Texas MD Anderson Cancer Center
- National Cancer Institute (T32CA009666, K08CA160692)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- melanoma, nivolumab, ipilimumab, combination immunotherapy, pathological complete response, T cell infiltration, lymphocyte infiltration, treatment-related adverse events, biomarkers
- MeSH terms
- Ipilimumab, Nivolumab, Adult, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Melanoma, Middle Aged, Neoplasm Staging, Risk Factors, Disease-Free Survival, Neoadjuvant Therapy, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
